|
| Disease/pathogen | Use of high throughput | Main result |
|
| Leishmania infantum chagasi | Mechanisms involved in parasite resistance to treatment | Identification of 32 differentially expressed proteins in miltefosine sensitive and resistant parasites using comparative proteomics [69] |
|
| Leishmania infantum | Mechanisms involved in parasite resistance to treatment | Identification of 97 differentially expressed proteins in amphotericin B-sensitive and -resistant parasites using quantitative proteomics [70] |
|
| Trypanosoma cruzi | Mechanisms involved in parasite resistance to treatment | Identification of proteins involved in the effect of naphthoimidazoles N1, N2 and N3 on the parasite using proteomics [71] |
|
| Trypanosoma cruzi | Mechanisms of drug action and resistance | Identification of proteins that could be related to benznidazole reductive activation and/or resistance mechanisms [72] |
|
| Trypanosoma brucei | Drug development | Proteomics study showing that 2,4-diaminopyrimidines have a good in vitro and in vivo pharmacological profile against trypanosomatid protozoans [73] |
|
| Toxoplasma gondii | Mechanisms involved in parasite resistance to treatment | First proteomics insights into sulfadiazine resistance in T. gondii resistant strains isolated from clinical cases [74] |
|
| Plasmodium falciparum | Drug development and mechanisms of drug action | Proteomics study showing that indolone-N-oxide causes a profound destabilization of the malaria-infected erythrocytes membrane through a mechanism apparently triggered by the activation of a redox signaling pathway rather than direct oxidative damage [75] |
|
| Plasmodium falciparum | Mechanisms involved in parasite resistance to treatment | Identification of a specific response to doxycycline treatment, involving mitochondrion and apicoplast [76] |
|
| Mycobacterium tuberculosis | Identification of markers of treatment response | Identification of a nonculture based, five-marker signature predictive of 8-week culture status using proteomics [77] |
|
| Neisseria gonorrhoeae | Drug resistance and mechanisms of drug action | Comparative proteomics study providing knowledge of the mode of action of antibiotic and secondary target proteins implicated in adaptation and compensatory mechanisms [78] |
|
| Staphylococcus aureus | Drug development and mechanisms of drug action | Proteomics study showing that MntABC might be a potential therapeutic target for the development of antibiotics and that in vivo proteomics data will serve as a valuable basis for defining potential antigen combinations for multicomponent vaccines [79] |
|
| Cancer | Drug development and mechanisms of drug action | First proteomic analysis regarding Aubipyc cytotoxicity in A2780/S ovarian cancer cell line showing that Aubipyc treatment affected, directly or indirectly, several glycolytic enzymes [80] |
|
| Cancer | Drug development | Proteomics study showing that several metabolism-related proteins, molecular chaperons, and proteins involved in signaling are differently expressed after targeted chemotherapeutic treatment (Daunorubicin-GnRH-III Derivative Bioconjugate), leading to the conclusion that the bioconjugate exerts its cytotoxic action by interfering with multiple intracellular processes [81] |
|
| Cancer | Drug development and mechanisms of drug action | Proteomics study showing differential protein expression after treatment of Hepatocellular Carcinoma Cell Lines with Alendronate [82] |
|
